Movement Alert｜Twist Bioscience Rises 5.62% in Regular Trading, Boosted by Investment Bank Target Price of $90

Market Focus06-19

On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.

On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, significantly above the analyst consensus target price of $73.12 according to FactSet. The elevated target price has provided sustained upward pressure on the stock over recent sessions, with shares climbing from approximately $80 on June 15 to current levels, representing a cumulative gain of roughly 9% over the period.

Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, combining proprietary software with scalable commercial infrastructure to serve healthcare, food and agriculture, industrial chemicals, and data storage sectors. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171651709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-19 03:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171651709","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Rises 5.62% in Regular Trading, Boosted by Investment Bank Target Price of $90","media":"Market Focus","content":"<p><p>On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.</p><p>On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, significantly above the analyst consensus target price of $73.12 according to FactSet. The elevated target price has provided sustained upward pressure on the stock over recent sessions, with shares climbing from approximately $80 on June 15 to current levels, representing a cumulative gain of roughly 9% over the period.</p><p>Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, combining proprietary software with scalable commercial infrastructure to serve healthcare, food and agriculture, industrial chemicals, and data storage sectors. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Rises 5.62% in Regular Trading, Boosted by Investment Bank Target Price of $90</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Rises 5.62% in Regular Trading, Boosted by Investment Bank Target Price of $90\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-19 03:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.</p><p>On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, significantly above the analyst consensus target price of $73.12 according to FactSet. The elevated target price has provided sustained upward pressure on the stock over recent sessions, with shares climbing from approximately $80 on June 15 to current levels, representing a cumulative gain of roughly 9% over the period.</p><p>Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, combining proprietary software with scalable commercial infrastructure to serve healthcare, food and agriculture, industrial chemicals, and data storage sectors. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1171651709","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171651709","pubTimestamp":1781812695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.On the news front, Canaccord Genuity issued a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"动向提示|Twist Bioscience常规交易涨5.62%，受投行目标价90美元提振","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, significantly above the analyst consensus target price of $73.12 according to FactSet. The elevated target price has provided sustained upward pressure on the stock over recent sessions, with shares climbing from approximately $80 on June 15 to current levels, representing a cumulative gain of roughly 9% over the period.Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, combining proprietary software with scalable commercial infrastructure to serve healthcare, food and agriculture, industrial chemicals, and data storage sectors. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171651709","isCrawlerRequest":true}